2914 On Other Exchanges
Symbol
Exchange
2914 is not on other exchanges.

japan tobacco inc (2914) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JAPAN TOBACCO INC (2914)
\

Related News

No related news articles were found.

japan tobacco inc (2914) Related Businessweek News

View More BusinessWeek News

japan tobacco inc (2914) Details

Japan Tobacco Inc., together with its subsidiaries, manufactures and sells tobacco products, primarily cigarettes in Japan and internationally. It also distributes imported tobacco products. The company offers its tobacco products primarily under the Winston, Camel, Mevius, LD, Benson & Hedges (B&H), Glamour, Sobranie, Silk Cut, Natural American Spirit, Seven Stars, Pianissimo, Peace, HOPE, and other brand names. In addition, it engages in the research and development, manufacture, and sale of prescription drugs in the fields of metabolic diseases, viral infection, and autoimmune/inflammatory diseases. The company’s pharmaceutical products include Riona tablets for the treatment of hyperphosphatemia, Remitch capsules for pruritus, and KAYEXALATE dry syrup for hyperkalemia; FUTHAN for injection, a protease inhibitor; ANTEBATE, a topical corticosteroid; CEDARTOLEN sublingual immunotherapy drugs; MITICURE House Dust Mite sublingual tablets; and Truvada, Stribild, Genvoya, and Descovy combination tablets for HIV. Further, it manufactures and sells staple food products, including frozen noodles, frozen rice, packed-cooked rice, and frozen baked bread; bakery products; and seasonings, including yeast extracts and oyster sauce. Japan Tobacco Inc. was founded in 1898 and is headquartered in Tokyo, Japan.

44,667 Employees
Last Reported Date: 03/24/17
Founded in 1898

japan tobacco inc (2914) Top Compensated Officers

Member of the Board
Total Annual Compensation: ¥93.0M
Representative Director
Total Annual Compensation: ¥154.0M
Compensation as of Fiscal Year 2016.
japan tobacco inc
Japan Tobacco Inc. Reports Preliminary Operating and Sales Results for the Month and Year to Date Ended December 2017

Japan Tobacco Inc. reported preliminary operating and sales results for the month and year to date ended December 2017. For the month, the company reported sales volume of 8.0 billion of cigarettes against 9.6 billion of cigarettes a year ago. For the year to date, the company reported sales volume of 92.9 billion of cigarettes against 106.2 billion of cigarettes a year ago. For December 2017, Japanese domestic cigarette revenue was ¥47.7 billion against ¥57.0 billion a year ago. For the year to date, Japanese domestic cigarette revenue was ¥552.9 billion against ¥623.8 billion a year ago.

Japan Tobacco Favors Regional Deals Over Complex Acquisitions

Japan Tobacco Inc. (TSE:2914)'s Chief Executive Officer, Masamichi Terabatake recently disclosed that Japan Tobacco favours pursuing deals in South-east Asia and markets where it lacks a presence as it actively seeks to expand overseas. The world's third-largest listed tobacco company is aiming to command around a 40 per cent share of the heated tobacco market in Japan by 2020, said Masamichi Terabatake in an interview.

Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. Announces Results of Phase 3 Comparative Study

Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. announced the top-line results of Phase 3 comparative study. This study is a part of the Phase 3 program for JTE-052, conducted in Japan, for the treatment of atopic dermatitis. This study is a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of JTE-052 ointment in comparison to placebo over 4 weeks in patients with atopic dermatitis. In the top-line results, the primary endpoint of efficacy, the change of the mEASI score from baseline, has met superiority to placebo. Furthermore, there were no clinically significant findings on safety and tolerability of JTE-052 ointment within the treatment period.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

2914 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2914.
View Industry Companies
 

Industry Analysis

2914

Industry Average

Valuation 2914 Industry Range
Price/Earnings 16.5x
Price/Sales 3.2x
Price/Book 2.5x
Price/Cash Flow 15.4x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JAPAN TOBACCO INC, please visit www.jt.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.